![]() |
|
|
Vol. 296, Issue 1, 150-159, January 2001
Department of Neuroscience Therapeutics, Pfizer Global Research and
Development, Ann Arbor Laboratories, Ann Arbor, Michigan
The use of trifluoroperazine in a well washed rat brain membrane
preparation revealed [3H]ifenprodil binding to a single
high affinity state with the pharmacology of
N-methyl-D-aspartate (NMDA) receptors
containing NR2B subunits. Inhibition of [3H]ifenprodil
binding in the presence of trifluoroperazine by 10 NR1a/NR2B selective
agents was highly correlated with their inhibition at rat NR1a/NR2B
receptors expressed in Xenopus ooctyes and
[3H]TCP binding to rat brain NR2B subunit containing NMDA
receptors but not with their inhibition of [3H]DTG
binding. Allosteric interactions with polyamines, Mg2+,
Zn2+, glutamate, glycine, and their antagonists were
consistent with NMDA receptors with NR2B subtype pharmacology. The rank
order of polyamine inhibition was spermine > spermidine > 1,5-(diethylamino)piperidine > arcaine > agmatine > putrescine. Both spermidine and MgCl2 shifted the
inhibition curve of ifenprodil to the right in a parallel manner, but
Mg2+ did not appear to be additive to spermidine. Glutamate
increased and glycine decreased the binding. Conversely, CPP decreased
the binding, and MDL 105,519 increased the binding in an agonist
reversible manner. The increase with MDL 105,519 and glutamate appeared
to be additive as did the decrease with glycine and CPP. Changes in the
buffer pH between 6.5 and 8.0 did not affect the affinity of NR2B
agents. Cirazoline but not clonidine inhibited the binding. MK-801 and
agents from various other pharmacological classes did not significantly
inhibit [3H]ifenprodil binding.
[3H]Ifenprodil binding in the presence of
trifluoroperazine appears to be selective for the voltage-independent
ifenprodil site on NMDA receptors containing the NR2B subunit.
This article has been cited by other articles:
![]() |
T. Johansson, P.-A. Frandberg, F. Nyberg, and P. Le Greves Molecular Mechanisms for Nanomolar Concentrations of Neurosteroids at NR1/NR2B Receptors J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 759 - 768. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Rachline, F. Perin-Dureau, A. Le Goff, J. Neyton, and P. Paoletti The Micromolar Zinc-Binding Domain on the NMDA Receptor Subunit NR2B J. Neurosci., January 12, 2005; 25(2): 308 - 317. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. M. Andre, J. Flores-Hernandez, C. Cepeda, A. J. Starling, S. Nguyen, M. K. Lobo, H. V. Vinters, M. S. Levine, and G. W. Mathern NMDA Receptor Alterations in Neurons from Pediatric Cortical Dysplasia Tissue Cereb Cortex, June 1, 2004; 14(6): 634 - 646. [Abstract] [Full Text] [PDF] |
||||